Zobrazeno 1 - 10
of 271
pro vyhledávání: '"Oscar Juan"'
Autor:
Esther Conde, MD, PhD, Susana Hernandez, PhD, Jose Luis Rodriguez Carrillo, MD, Rebeca Martinez, APT, Marta Alonso, APT, Daniel Curto, MD, Beatriz Jimenez, MD, Alejandra Caminoa, MD, PhD, Amparo Benito, MD, Pilar Garrido, MD, PhD, Sergi Clave, PhD, Edurne Arriola, MD, PhD, Isabel Esteban-Rodriguez, MD, PhD, Javier De Castro, MD, PhD, Irene Sansano, MD, Enriqueta Felip, MD, PhD, Federico Rojo, MD, PhD, Manuel Dómine, MD, PhD, Ihab Abdulkader, MD, PhD, Jorge Garcia-Gonzalez, MD, Cristina Teixido, PhD, Noemi Reguart, MD, PhD, Desamparados Compañ, MD, PhD, Amelia Insa, MD, Nuria Mancheño, MD, PhD, Sarai Palanca, MD, PhD, Oscar Juan-Vidal, MD, PhD, Nuria Baixeras, MD, Ernest Nadal, MD, PhD, Maria Cebollero, MD, Antonio Calles, MD, Paloma Martin, MD, PhD, Clara Salas, MD, PhD, Mariano Provencio, MD, PhD, Ignacio Aranda, MD, PhD, Bartomeu Massuti, MD, Laura Lopez-Vilaro, MD, Margarita Majem, MD, PhD, Luis Paz-Ares, MD, PhD, Fernando Lopez-Rios, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100653- (2024)
Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencin
Externí odkaz:
https://doaj.org/article/a3e58ca9d39948fda3972ff1d75a8f34
Autor:
Enriqueta Felip, David P. Carbone, Martin Reck, Luis Paz-Ares, Yong Yuan, Nan Hu, Niels Reinmuth, Xiaoqing Zhang, Thomas John, Ying Cheng, Shun Lu, Manuel Cobo, Michael Schenker, Tudor-Eliade Ciuleanu, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Eduardo Richardet, Hideaki Mizutani, Bogdan Zurawski, Aurelia Alexandru, Javed Mahmood, Tuli De, Irene Santi, John R. Penrod, Adam Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a mi
Externí odkaz:
https://doaj.org/article/c372aee3045841d7bf925f1ae98c8480
Autor:
Rohit Joshi, Sylvia Adams, Jiang Shao, Wen Xu, Joanne Chiu, William Lawler, Muhammad Furqan, Ulka N Vaishampayan, Oscar Juan-Videl, Natalie Rainey, Bruno Fang, Brian Vicuna, Fadi Shihadeh, Ann Chen, Aoife Sills, Estibaliz Lopez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/36856df85def4993a51ba3ab47f19963
Autor:
Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Virginia Calvo, Enric Carcereny, Alexandra Cantero, Reyes Bernabé, Gretel Benitez, Rafael López Castro, Bartomeu Massutí, Edel del Barco, Rosario García Campelo, Maria Guirado, Carlos Camps, Ana Laura Ortega, Jose Luis González Larriba, Alfredo Sánchez, Joaquín Casal, M. Angeles Sala, Oscar Juan-Vidal, Joaquim Bosch-Barrera, Juana Oramas, Manuel Dómine, Jose Manuel Trigo, Remei Blanco, Julia Calzas, Idoia Morilla, Airam Padilla, Joao Pimentao, Pedro A. Sousa, Maria Torrente
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself.
Externí odkaz:
https://doaj.org/article/0111fe9f31fa49208eab155d42059c73
Autor:
Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern
Externí odkaz:
https://doaj.org/article/299f8904a44340aa8e9fdf450ecbbc4b
Autor:
Zoran Andric, MD, Gabriella Gálffy, MD, Manuel Cobo Dols, MD, Barna Szima, MD, Goran Stojanovic, MD, Marina Petrovic, MD, Enriqueta Felip, MD, David Vicente Baz, MD, Santiago Ponce Aix, MD, Oscar Juan-Vidal, MD, Zsuzsanna Szalai, MD, Gyorgy Losonczy, MD, Antonio Calles Blanco, MD, Reyes Bernabe, MD, Gema García Ledo, MD, Andrés Aguilar Hernández, MD, Klaus Duecker, PhD, Dongli Zhou, PhD, Andreas Schroeder, MD, Guelseren Guezel, MD, Fortunato Ciardiello, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100461- (2023)
Introduction: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. Methods: Patients with recurrent or metastatic
Externí odkaz:
https://doaj.org/article/283d0b24db6b460b8d6628f029ba7cc0
Autor:
Guillermo Suay, Juan-Carlos Garcia-Cañaveras, Francisco Aparisi, Agustin Lahoz, Oscar Juan-Vidal
Publikováno v:
Cancers, Vol 15, Iss 18, p 4433 (2023)
Non-small cell lung cancer (NSCLC) is one of the world’s leading causes of morbidity and mortality. ICIs alone or combined with chemotherapy have become the standard first-line treatment of metastatic NSCLC. The impressive results obtained have sti
Externí odkaz:
https://doaj.org/article/345a4c159a174dad988b473699e066ad
Autor:
Lourdes Gutiérrez, Ana Royuela, Enric Carcereny, Rafael López-Castro, Delvys Rodríguez-Abreu, Bartomeu Massuti, José Luis González-Larriba, Rosario García-Campelo, Joaquim Bosch-Barrera, María Guirado, Carlos Camps, Manuel Dómine, Reyes Bernabé, Joaquín Casal, Juana Oramas, Ana Laura Ortega, Mª. Angeles Sala, Airam Padilla, David Aguiar, Oscar Juan-Vidal, Remei Blanco, Edel del Barco, Natividad Martínez-Banaclocha, Gretel Benítez, Blanca de Vega, Ainhoa Hernández, Maria Saigi, Fernando Franco, Mariano Provencio
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. Me
Externí odkaz:
https://doaj.org/article/233d05bfad794aa8b762c296fe046b5c
Autor:
Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to descri
Externí odkaz:
https://doaj.org/article/8ebc0e8ffdc84091be87e3c5b709643d
Autor:
Atocha Romero, Eloisa Jantus‐Lewintre, Beatriz García‐Peláez, Ana Royuela, Amelia Insa, Patricia Cruz, Ana Collazo, Javier Pérez Altozano, Oscar Juan Vidal, Pilar Diz, Manuel Cobo, Berta Hernández, Sergio Vázquez Estevez, Gretel Benítez, Maria Guirado, Margarita Majem, Reyes Bernabé, Ana Laura Ortega, Ana Blasco, Joaquim Bosch‐Barrera, Jose M. Jurado, Jorge García González, Santiago Viteri, Carlos Garcia Giron, Bartomeu Massutí, Ana Lopez Martín, Alejandro Rodriguez‐Festa, Silvia Calabuig‐Fariñas, Miguel Ángel Molina‐Vila, Mariano Provencio
Publikováno v:
Molecular Oncology, Vol 15, Iss 1, Pp 43-56 (2021)
Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. Herein, seven methodolo
Externí odkaz:
https://doaj.org/article/fee84be40c92476693b579001138154a